Idera senior vice president of business development and strategic initiatives Clayton Fletcher said: "We are excited to be working with GSK to apply our drug discovery and development efforts in renal disease. This collaboration broadens the utility of our third generation antisense platform beyond the stated areas of focus for Idera in cancers and rare diseases.
"Importantly, through such collaborations we have the opportunity to strengthen our balance sheet to enable us to further our own clinical development and commercial aspirations."
Under the terms of the agreement, Idera is eligible to receive approximately $100m in development and regulatory milestone payments, including a $2.5m upfront payment.
Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500m.
GSK senior vice president and head of the metabolic pathways and cardiovascular therapy area unit John Lepore said: "Advances in our understanding of chronic kidney disease have opened up new treatment opportunities.
"Idera’s antisense platform offers a new path to explore whether gene silencing technology can help stop or slow chronic kidney disease."